Noopept, pills 10mg, 50pcs

Composition

Active ingredient:  

Omberacetam (noopept) – 10.0 mg;

excipients:  

lactose monohydrate-55.0 mg,

potato starch-13.5 mg,

microcrystalline cellulose 101-21.2 mg,

magnesium stearate-0.3 mg,

povidone (polyvinyl-pyrrolidone, povidone K-25) – 0.0008 mg

Pharmacological action

Pharmacotherapy group: nootropic agent.

ATX code: N06 BX

Pharmacological properties

Pharmacodynamics

Noopept ® has nootropic and neuroprotective properties. Improves learning ability and memory by acting on all phases of processing: initial information processing, consolidation, and retrieval. Prevents the development of amnesia caused by electric shock, blockade of central cholinergic structures, glutamatergic receptor systems, and deprivation of the periodoxic phase of sleep.

The neuroprotective (protective) effect of Noopept® is manifested in increasing the resistance of brain tissue to damaging effects (trauma, hypoxia, electroconvulsive, toxic) and reducing the degree of damage to brain neurons.

The drug reduces the volume of the focus on the thrombotic model of stroke and prevents the death of neurons in the culture of the cerebral cortex and cerebellum tissue exposed to neurotoxic concentrations of glutamate, free radical oxygen.

Noopept ® has an antioxidant effect, blocks potential-dependent calcium channels of neurons, weakening the neurotoxic effect of excess calcium, improves the rheological properties of blood, having antiplatelet, fibrinolytic, anticoagulant properties.

The nootropic effect of the drug is associated with the formation of cycloprolylglycine, which is similar in structure to the endogenous cyclic dipeptide with anti-amnesic activity, as well as with the presence of a cholinopositive effect.

Noopept ® increases the amplitude of the transcallosal response, facilitating associative connections between the cerebral hemispheres at the level of cortical structures. Promotes the restoration of memory and other cognitive functions that are impaired as a result of damaging effects – brain injury, local and global ischemia, prenatal damage (alcohol, hypoxia).

The therapeutic effect of the drug in patients with organic disorders

of the central nervous system is manifested starting from 5-7 days of treatment. Initially, the anxiolytic and mild stimulating effects available in the spectrum of activity of Noopept®are realized, which are manifested in the reduction or disappearance of anxiety, increased irritability, affective lability, and sleep disorders. After 14-20 days of therapy, a positive effect of the drug on cognitive functions, attention and memory parameters is revealed.

Noopept ® has a vegetative-normalizing effect, helps to reduce headaches, orthostatic disorders, and tachycardia.

When the drug is discontinued, there is no “withdrawal”syndrome.

It does not have a damaging effect on internal organs; it does not lead to changes in the cellular composition of blood and biochemical parameters of blood and urine; it does not have an immunotoxic, teratogenic effect, and does not exhibit mutagenic properties.

Pharmacokinetics

Omberacetam, absorbed in the gastrointestinal tract, enters the systemic bloodstream unchanged, penetrates the blood-brain barrier, and is detected in the brain in higher concentrations than in the blood. The average time to reach the maximum concentration is 15 minutes. The half-life from blood plasma is 0.38 hours. It is partially preserved unchanged, partially metabolized to form phenylacetic acid, phenylacetylproline and cycloprolylglycine. It has a high relative bioavailability (99.7%), does not accumulate in the body, and does not cause drug dependence.

Indications

Disorders of memory, attention, and other cognitive functions and emotionally labile disorders (including in elderly patients) in the presence of:

• consequences of traumatic brain injury,

• post-commotion syndrome,

• vascular brain failure (encephalopathies of various origins),

• asthenic disorders,

• and other conditions with signs of reduced intellectual productivity.

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy.

If it is necessary to use the drug during breastfeeding, it is necessary to resolve the issue of stopping breastfeeding.

Contraindications

Pregnancy, breast-feeding period. Under 18 years of age. Hypersensitivity to the components of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Severe liver and kidney dysfunction.

Side effects

Possible allergic reactions.

In patients with arterial hypertension, mainly severe, against the background of taking the drug, an increase in blood pressure may occur.

Interaction

No interaction of Noopept® with alcohol, sleeping pills, antihypertensive agents and psychostimulants has been established.

How to take, course of use and dosage

Noopept® is applied orally, after meals. Treatment begins with a dose of 20 mg, distributed in two doses of 10 mg during the day (morning and afternoon). If the effectiveness of therapy is insufficient and the drug is well tolerated, the dose is increased to 30 mg (see “Special Instructions”), distributing it in three doses of 10 mg per day. Do not take the drug later than 18 hours. The duration of the course of treatment is 1.5-3 months. A second course of treatment, if necessary, can be carried out in 1 month.

Overdose

Specific manifestations of overdose have not been established.

Special instructions

If you need to increase the dose of the drug (up to 30 mg/day), with prolonged use, as well as with simultaneous use with other drugs, the appearance of adverse reactions or deterioration of the condition, you should consult a doctor.

Influence on the ability to drive vehicles and mechanisms

Noopept®does not affect the ability to drive mechanisms and vehicles.

Form of production

Tablets,10 mg.

25 tablets each in a contour cell package made of polyvinyl chloride film and aluminum foil.

2 contour cell packagings together with the instructions for use are placed in a pack of cardboard.

Storage conditions

At a temperature not exceeding 25 °C. Keep out of reach of children.

Shelf life

3 years

Active ingredient

Omberacetam

Dosage form

Tablets

Description

For adults

Indications

Alzheimer’s disease, Asthenia, Concussion and other traumatic brain injuries, Circulatory disorders, Acquired dementia